PropThink: Celgene Nearing 52-week High on Abraxane Data, Upcoming PDUFA

[ACN Newswire] – By Jake KingCelgene (NASDAQ:CELG) moved closer today to securing another indication for its oncology drug, Abraxane, which is already approved as a second-line treatment for metastatic breast cancer. On … more

View todays social media effects on CELG

View the latest stocks trending across Twitter. Click to view dashboard